Trial reportJournal of gastrointestinal cancer2025
A Randomized Controlled Trial of Stereotactic Body Radiation Therapy Versus Chemoradiation Following Induction Chemotherapy in Borderline Resectable and Locally Advanced Pancreatic Cancer.
Trial report in Journal of gastrointestinal cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Review
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeAdenocarcinoma of pancreas is a lethal malignancy with multimodality treatment used in various combinations to improve survival. This study aimed to evaluate resectability rates, R0 resection status, and local progression-free survival (LPFS) in borderline resectable pancreatic cancer (BRPC) and locally advanced pancreatic cancer (LAPC) patients treated with neoadjuvant chemotherapy (NACT) followed by either stereotactic body radiotherapy (SBRT) or conventional chemoradiation (CRT).
methodsIn this single institution prospective study, 20 pancreatic cancer patients (15 LAPC and 5 BRPC) received NACT (modified FOLFIRINOX or Gemcitabine with nab-paclitaxel), followed by random assignment (1:1) to SBRT (33-42 Gy/5-6 fractions) or CRT (45 Gy in 25 fractions with Capecitabine). After restaging, patients who were eligible underwent surgery, while others continued chemotherapy. Toxicity, quality of life (QoL), and haematological parameters (NLR, PLR) were assessed.
resultsResectability was observed in 15% of patients, all from the SBRT arm. All patients who underwent resection were LAPC at diagnosis. The mean overall survival (OS) and local progression-free survival (LPFS) in the SBRT group were 21.8 months and 14 months, respectively, with a median OS of 15 months and median LPFS of 11 months. In comparison, the CRT group had a mean OS and LPFS of 13 months and 8.6 months, respectively, with a median OS of 12 months and median PFS of 7 months. One-year OS was 80% in the SBRT arm and 45% in the CRT arm. QOL improved in both arms, with better scores in the SBRT group. SBRT had no grade 3 or 4 toxicities. Lower NLR and PLR values correlated with better outcomes.
conclusionSBRT showed superior resectability, survival outcomes, and QoL compared to CRT in patients with BRPC and LAPC. However, due to the study's small sample size and single-centre design, these findings are hypothesis-generating and warrant validation in larger multicentre trials.
Indexed as
Identifiers
41144077What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.